Ultrasound Molecular Agent Gets FDA Fast Track Designation for Active Bowel Inflammation with Crohn’s Disease
Phase 2 studies of the BR55 ultrasound contrast agent reportedly demonstrated a 95 percent accuracy in showing the expression of vascular endothelial growth factor receptor 2 (VEGFR2) in bowel segments reflecting active inflammation in patients with Crohn’s disease.
The Food and Drug Administration (FDA) has granted fast track designation to BR55, an emerging molecular ultrasound contrast agent, for the diagnosis of active bowel inflammation in patients with Crohn’s disease.
Targeting the vascular endothelial growth factor receptor 2 (VEGFR2), the injection of BR55 (perfluorobutane/nitrogen lipopeptide-coated microbubbles) achieved a 95 percent accuracy in revealing active bowel inflammation in patients with Crohn’s disease in phase 2 studies, according to Bracco Imaging, the developer of the ultrasound contrast agent.
The company maintained that the use of BR55 to detect angiogenesis through non-invasive, radiation-free ultrasound imaging may enhance monitoring and facilitate timely treatment in this patient population.
“The FDA fast track process is aimed at improving the management of patients with serious conditions and filling an unmet medical need, such as the accurate monitoring of disease activity in patients with Crohn's disease,” noted Alberto Spinazzi, M.D., the chief medical and regulatory officer for the Bracco Imaging Group. “This fast track designation supports our goal to get BR55 to the patient earlier and more efficiently."
Bracco Imaging noted that the efficacy and safety of BR55 will be evaluated in forthcoming multicenter, multinational phase 3 studies.
Recent Videos
Related Content
BrightHeart Garners Third FDA Clearance for AI-Powered Assessments of Fetal Heart Ultrasound
May 14th 2025Article
The latest FDA 510(k) clearance is for B-Right Views, an AI-enabled device, which provides automated detection of required views necessary for second- and third-trimester fetal heart ultrasound exams.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025Podcast
In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025Article
For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020Podcast
In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
